Q-omics provides the consensus-scored YME1L1 profile across patient tissues and cancer cell-line models. YME1L1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, YME1L1 is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, YME1L1 protein abundance shows 38,287 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, LIHC, and LSCC as cancer lineages where YME1L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YME1L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YME1L1 survival associations across molecular data types. YME1L1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YME1L1 RNA expression–survival associations across cancer types. High YME1L1 expression shows unfavorable associations in ACC, BLCA, LIHC, CESC and UVM, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for YME1L1 RNA expression.
This table summarizes YME1L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 11. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for YME1L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YME1L1 shows higher tumor expression in LIHC, BRCA, STAD, LUSC, LUAD and BLCA. The LIHC box plot shows higher YME1L1 RNA expression in tumor versus normal tissue (log2 FC = +0.710, t-test p < 0.001).
This table shows molecular features associated with YME1L1 in patient tissues and cancer cell lines. In patient samples, YME1L1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, YME1L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
